



**AUSTRALIA BIOTECH
INVEST & PARTNERING 2018**
Connecting capital with innovation

Tuesday 30 October
Sofitel Melbourne on Collins
ausbiotechinvestment.com.au

#AusBioInv



Company profile

KAZIA THERAPEUTICS LIMITED

(ASX: KZA; NASDAQ: KZIA)

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Kazia works in partnership with the world's leading drug developers and researchers to bring forward impactful therapies for patients with cancer. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019. An investigator-initiated collaboration with St Jude Children's Research Hospital in DIPG, a rare form of childhood brain cancer, commenced in October 2018. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

For more information, please visit www.kaziatherapeutics.com, or follow us on Twitter at @KaziaTx.

Speaker Profile

DR JAMES GARNER

Chief Executive Officer & Managing Director
Kazia Therapeutics Limited

Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical through to commercialisation, and he has been involved in the development and approval of a number of commercially successful pharmaceutical products.





Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore. Dr Garner is a member of the Australian Institute of Company Directors.